Sacramento-based UC Davis Comprehensive Cancer Center will use next generation sequencing analysis on patients diagnosed with hematological malignancies and pancreatic cancer.
The strategy will be deployed through a partnership with Tempus, a health technology company focused on personalized oncology care. Under the partnership, Tempus will work with a team of investigators led by Primo Lara, MD, interim director of the UC Davis Comprehensive Cancer Center.
Tempus will use machine learning and advanced bioinformatics to support physicians as they analyze patient molecular data. The goal of the partnership is to identify patterns to guide treatment for patients who are unlikely to respond to standard therapies.